Tests tenofovir alafenamide in people with chronic hepatitis B and normal liver enzymes
Tests tenofovir alafenamide in adults with chronic hepatitis B and normal ALT.
Plain-language title generated from the registry record
Registry title: Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
Key facts
- Where
- Guangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT04231565, who can take part
Where in China
- Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Third Affiliated Hospital, Sun Yat-Sen University
- Trial code
- NCT04231565
- Record updated
- 1 March 2024
- Original description
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.Read full original descriptionShow less
Study on Therapeutic Effects and Safety of Nucleoside (Acid) Analogues Treatment in Patients With Chronic Hepatitis B With Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA: a Randomized Controlled Trial
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
Inclusion: Positive hepatitis b surface antigen and hepatitis b antibody > 0.5 year; Age from 18 to 65 years old; Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks; Positive Hepatitis b virus(HBV); Do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year.
Exclusion: Other active liver diseases; Hepatocellular carcinoma or other malignancy; Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate; Pregnancy or lactation.